Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy and Safety Profile of LB-102 as an Antipsychotic for Adults Experiencing Acute Schizophrenia: A Randomized Study

  • By

  • Anna Eramo

  • Christoph U. Correll

  • David P. Walling

  • Rishi Kakar

  • Niccolo Bassani

  • Leslie Callahan

  • Baker P. Lee

  • Zachary Prensky

  • Andrew R. Vaino

  • John M. Kane

  • July 1, 2026

Share

Original Source(s)

Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized

  • by Anna Eramo, Christoph U. Correll, David P. Walling, Rishi Kakar, Niccolo Bassani, Leslie Callahan, Baker P. Lee, Zachary Prensky, Andrew R. Vaino, John M. Kane

  • July 1, 2026

Related Content

Correction: Altered N170 and compensatory mechanisms in face processing in schizophrenia: an event-related potential study

Emerging non-D2 receptor-based therapies for schizophrenia: a focus on muscarinic and glutamatergic pathways

Transcranial focused ultrasound stimulation in schizophrenia: current evidence, mechanisms, and future directions